An Advanced Echocardiographic Evaluation of Nebivolol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01206439|
Recruitment Status : Terminated (Slow enrollment)
First Posted : September 21, 2010
Results First Posted : November 25, 2015
Last Update Posted : February 15, 2018
|Condition or disease||Intervention/treatment||Phase|
|Hypertension||Drug: nebivolol||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Advanced Echocardiographic Evaluation of Nebivolol|
|Study Start Date :||September 2010|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||August 2012|
Experimental: Nebivolol 5 or 10 mg, oral, daily
Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol 5 or 10 mg oral, daily
Other Name: Bystolic
- Change in Systolic and Diastolic Myocardial Function [ Time Frame: Baseline to day 180 ]Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.
- Exercise Tolerance [ Time Frame: Baseline to day 180. ]Changes in exercise tolerance and time from baseline to 180 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01206439
|United States, Ohio|
|University of Cincinnati|
|Cincinnati, Ohio, United States, 45267|
|Principal Investigator:||Jack Rubinstein, MD||University of Cincinnati|